Search - tctmd.com

Displaying 301 - 320 of 477

Sort: Relevancy | Date

Presentation TCT 2014

Definitely To Prevent Stent Thrombosis and MI!

Presenter: Gregg W. Stone

September 15, 2014

Presentation TCT 2014

Definitely Not An Expensive Way to Increase Bleeding Without Much Benefit!

Presenter: Nick Curzen

September 15, 2014

Presentation TCT 2014

TCT 460: Bivalirudin Versus Heparin During Percutaneous Coronary Intervention: A Meta-analysis of Randomized Trials

Presenter: John A. Bittl, Tullio Palmerini, Salvatore Cassese, MD

September 15, 2014

Presentation TCT 2014

TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Presenter: Stefan K. James, Cindy L. Grines, Tracy Y. Wang

September 15, 2014

Presentation TCT 2014

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation

Presenter: Roxana Mehran, Harvey D. White, Antonio Colombo

September 15, 2014

Presentation TCT 2014

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation

Presenter: Roxana Mehran, Harvey D. White, Nikolaus Sarafoff

September 15, 2014

Presentation TCT 2014

BRIGHT: A Prospective, Randomized Trial of Bivalirudin Monotherapy Versus Heparin Monotherapy Versus Heparin Plus Tirofiban in Patients with Acute Myocardial Infarction Undergoing Coronary Intervention

Presenter: Roxana Mehran, Harvey D. White, Yaling Han

September 15, 2014

News Conference News TCT 2014

SYMPLICITY HTN-3 Substudy Examines BP Response Factors in African Americans

Yael L. Maxwell

September 15, 2014

Presentation TCT 2014

Does Cilostazol Have a Role as an Antiplatelet Agent in the Contemporary DES Era (and in Triple Therapy Decisions)?

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Frederick Feit

September 14, 2014

Presentation TCT 2014

Integrating a WOEST Aspirin Deletion Strategy Into Clinical Practice: When Is it Appropriate?

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Freek W.A. Verheugt

September 14, 2014

Presentation TCT 2014

Featured Lecture: First Presentation of the PLATO Primary PCI Subgroup

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Philippe Gabriel Steg

September 14, 2014

Presentation TCT 2014

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Matthew J. Price

September 14, 2014

Presentation TCT 2014

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Anthony A. Bavry

September 14, 2014

Presentation TCT 2014

TCT 481: Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus-Eluting Stent Implantation in OPTIMIZE

Presenter: Dietmar Trenk, Harvey D. White, Dominick J. Angiolillo, Fausto Feres

September 14, 2014

Presentation TCT 2014

TCT 479: The Increased Risk of Stent Thrombosis in Acute Coronary Syndromes Is Confined to the First 30 Days After PCI: Results from the Multicenter ADAPT-DES Study

Presenter: Dietmar Trenk, Harvey D. White, Dominick J. Angiolillo, Ajay J. Kirtane

September 14, 2014

Presentation TCT 2014

Time to Move to 3-6 Months Even in ACS!

Presenter: Marco Valgimigli

September 14, 2014

Presentation TCT 2014

Definitely Not the Data are Clear!

Presenter: Germano Di Sciascio

September 14, 2014

Presentation TCT 2014

Definitely the Data are Clear!

Presenter: E. Magnus Ohman

September 14, 2014

Presentation TCT 2014

TCT 467: Bivalirudin vs Heparin for Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Controlled Trials

Presenter: David J. Moliterno, E. Magnus Ohman, Duane S. Pinto, Michael Lipinski

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Heparin!

Presenter: Rod H. Stables

September 14, 2014

Advertisement

Definitely To Prevent Stent Thrombosis and MI!

Definitely Not An Expensive Way to Increase Bleeding Without Much Benefit!

TCT 460: Bivalirudin Versus Heparin During Percutaneous Coronary Intervention: A Meta-analysis of Randomized Trials

TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation

BRIGHT: A Prospective, Randomized Trial of Bivalirudin Monotherapy Versus Heparin Monotherapy Versus Heparin Plus Tirofiban in Patients with Acute Myocardial Infarction Undergoing Coronary Intervention

SYMPLICITY HTN-3 Substudy Examines BP Response Factors in African Americans

Does Cilostazol Have a Role as an Antiplatelet Agent in the Contemporary DES Era (and in Triple Therapy Decisions)?

Integrating a WOEST Aspirin Deletion Strategy Into Clinical Practice: When Is it Appropriate?

Featured Lecture: First Presentation of the PLATO Primary PCI Subgroup

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

TCT 481: Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus-Eluting Stent Implantation in OPTIMIZE

TCT 479: The Increased Risk of Stent Thrombosis in Acute Coronary Syndromes Is Confined to the First 30 Days After PCI: Results from the Multicenter ADAPT-DES Study

Time to Move to 3-6 Months Even in ACS!

Definitely Not the Data are Clear!

Definitely the Data are Clear!

TCT 467: Bivalirudin vs Heparin for Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Controlled Trials

The Data Strongly Support Heparin!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content